286,098 Shares in Establishment Labs Holdings Inc. $ESTA Purchased by Bamco Inc. NY

Key Points

• Bamco Inc. NY acquired 286,098 shares of Establishment Labs in the second quarter, valued at approximately $24.55 million and representing about 0.96% of the company. Institutional investors and hedge funds collectively own 72.91% of ESTA.
• Analyst sentiment remains broadly positive: eight analysts rate the stock a Buy and one rates it a Sell, producing a consensus “Moderate Buy” rating and an average price target of $100.25.
• Establishment Labs reported quarterly revenue of $67.54 million, up 31.7% year over year and above estimates, but its adjusted loss of $0.39 per share missed expectations. Shares opened at $72.45, below the 50-day moving average of $85.54.

Bamco Inc. NY bought a new position in Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 286,098 shares of the company's stock, valued at approximately $24,550,000. Bamco Inc. NY owned about 0.96% of Establishment Labs at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. KBC Group NV acquired a new stake in Establishment Labs in the first quarter worth about $28,000. Quarry LP acquired a new position in Establishment Labs during the 3rd quarter valued at about $34,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Establishment Labs during the 2nd quarter worth about $43,000. Kestra Advisory Services LLC bought a new stake in shares of Establishment Labs during the 4th quarter worth about $47,000. Finally, Osaic Holdings Inc. lifted its stake in shares of Establishment Labs by 900.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company's stock worth $85,000 after acquiring an additional 1,800 shares during the period. Institutional investors and hedge funds own 72.91% of the company's stock.

Analyst Upgrades and Downgrades

ESTA has been the subject of several recent analyst reports. JPMorgan Chase & Co. increased their price objective on shares of Establishment Labs from $84.00 to $95.00 and gave the company an "overweight" rating in a report on Friday, August 7th. TD Cowen upped their target price on Establishment Labs from $95.00 to $117.00 and gave the stock a "buy" rating in a research report on Monday, August 3rd. Mizuho increased their price target on Establishment Labs from $100.00 to $105.00 and gave the company an "outperform" rating in a research note on Wednesday, July 15th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Establishment Labs in a research report on Wednesday, June 24th. Finally, Canaccord Genuity Group set a $105.00 price objective on Establishment Labs in a research note on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Establishment Labs presently has a consensus rating of "Moderate Buy" and a consensus target price of $100.25.

Establishment Labs Trading Up 0.4%

Shares of NASDAQ:ESTA opened at $72.45 on Thursday. The firm has a fifty day moving average of $85.54 and a two-hundred day moving average of $74.92. The company has a quick ratio of 2.52, a current ratio of 3.84 and a debt-to-equity ratio of 12.11. Establishment Labs Holdings Inc. has a 12-month low of $36.53 and a 12-month high of $97.59. The firm has a market capitalization of $2.16 billion, a P/E ratio of -55.31 and a beta of 1.07.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.05). The firm had revenue of $67.54 million during the quarter, compared to analyst estimates of $65.79 million. Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%.The company's quarterly revenue was up 31.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.57) EPS. On average, equities analysts expect that Establishment Labs Holdings Inc. will post -1.15 EPS for the current fiscal year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company's proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company's flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.

Want to see what other hedge funds are holding ESTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source